Tandem Diabetes Care Inc. (TNDM) Releases Q4 2025 Earnings: Revenue Beats, EPS Narrower Loss

Tandem Diabetes Care Inc. (TNDM) reported fourth-quarter 2025 results showing modest revenue growth, improved gross profit, a small operating profit, and a slight net loss.

Revenue: $290.4 million, up 2.7% year-over-year.

Gross profit: $167.5 million, up 6.4% year-over-year.

Operating profit: $8.3 million (down sharply year-over-year, -1,525.1%).

Net result: reported a net loss of $0.6 million (net income attributable to common shareholders declined 178.0% year-over-year).

Diluted EPS: -0.01.

Cash from operations: $8.3 million, down 22.9% year-over-year.

Invested $4.1 million in property, plant and equipment (up 33.3% year-over-year).

Cash and cash equivalents: $91.9 million, up 32.8% year-over-year.

Cost of sales: $122.9 million, down 1.8% year-over-year.

Total liabilities: $725.9 million, up 3.0% year-over-year.

Revenue beat the consensus estimate of $282.6 million.

Diluted EPS of -0.01 compared with an estimate of -0.0964 (a smaller loss than expected).

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Tandem Diabetes Care Inc. Hedge Fund Activity

We have seen 135 institutional investors add shares of Tandem Diabetes Care Inc. stock to their portfolio, and 173 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

HOOD RIVER CAPITAL MANAGEMENT LLC removed 2,551,644 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $56,085,135
CITADEL ADVISORS LLC added 2,048,802 shares (+5147.6%) to their portfolio in Q4 2025, for an estimated $45,032,667
STEPHENS INVESTMENT MANAGEMENT GROUP LLC removed 1,737,769 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $21,096,515
DRIEHAUS CAPITAL MANAGEMENT LLC added 1,610,342 shares (+inf%) to their portfolio in Q4 2025, for an estimated $35,395,317
OPHIR ASSET MANAGEMENT PTY LTD removed 1,464,956 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $17,784,565
CHAMPLAIN INVESTMENT PARTNERS, LLC removed 1,455,123 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $17,665,193
MORGAN STANLEY added 1,342,950 shares (+182.1%) to their portfolio in Q4 2025, for an estimated $29,518,041

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Tandem Diabetes Care Inc. Congressional Stock Trading

Members of Congress have traded $TNDM stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $TNDM stock by members of Congress over the last 6 months:

REPRESENTATIVE JOSH GOTTHEIMER purchased up to $15,000 on 09/22.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

Tandem Diabetes Care Inc. Analyst Ratings

Wall Street analysts have issued reports on $TNDM in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Baird issued a "Outperform" rating on 12/16/2025
Barclays issued a "Overweight" rating on 11/10/2025
Canaccord Genuity issued a "Buy" rating on 09/29/2025
Oppenheimer issued a "Outperform" rating on 09/08/2025

To track analyst ratings and price targets for Tandem Diabetes Care Inc., check out Quiver Quantitative's $TNDM forecast page.

Tandem Diabetes Care Inc. Price Targets

Multiple analysts have issued price targets for $TNDM recently. We have seen 11 analysts offer price targets for $TNDM in the last 6 months, with a median target of $23.0.

Here are some recent targets:

Jonathan Block from Stifel set a target price of $20.0 on 02/04/2026
Lee Hambright from Bernstein set a target price of $25.0 on 01/09/2026
Richard Newitter from Truist Securities set a target price of $24.0 on 12/18/2025
William Plovanic from Canaccord Genuity set a target price of $35.0 on 12/17/2025
Anthony Petrone from Mizuho set a target price of $21.0 on 12/17/2025
Jeff Johnson from Baird set a target price of $30.0 on 12/16/2025
Joanne Wuensch from Citigroup set a target price of $22.0 on 12/11/2025